Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710655 | 0.84 | GRM5 (0.52) | GRM5 | |
| SCHEMBL4710329 | 0.73 | CYP1A2 (0.46) | GRM5FFAR1 | |
| SCHEMBL4711553 | 0.72 | GRM5 (0.41) | GRM5 | |
| SCHEMBL16918313 | 0.71 | LMNA (0.39) | GRM5LMNAFFAR1NPC1ALDH1A1 | |
| SCHEMBL4713235 | 0.70 | GRM5 (0.68) | GRM5 | |
| SCHEMBL30469478 | 0.68 | GRM5 (0.69) | GRM5FFAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30469481 | 0.68 | GRM5 (0.69) | GRM5FFAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4562089 | 0.68 | GRM5 (0.69) | GRM5FFAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16742902 | 0.67 | MEN1 (0.54) | LMNANPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4713737 | 0.67 | GRM5 (0.71) | GRM5LMNANPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |